Indegene Limited is a “digital-first” commercialization firm that is solely focused on the global life sciences business. Their solutions help biopharmaceutical, emerging biotech, and medical device firms create medicines, introduce them to market, and drive sales throughout their product life cycle in a more effective, efficient, and modern way. Indegene IPO will hit the stock market in April 2023.
Table of Contents
About Indegene
They can effectively update & digitize the essential tasks included in the life sciences commercialization process thanks to their comprehension of the healthcare industry.
To be able to organize and analyze scientific & clinical data, navigate the regulatory environment and the ethical standards within which the industry operates, & develop medical content for healthcare professionals, patients, and payers, it is necessary to have in-depth domain expertise of the journey of a drug or medical device from the research lab to the market.
Their teams are highly skilled in the field of healthcare, with 21.88% of their delivery employees (i.e., who do not work in corporate and support functions) holding degrees in fields related to healthcare, such as MD, MBBS, PhD, BDS, MPharm, & BPharm.
Growth
They feel they are in a good position to profit from the anticipated increase in life sciences operations spending, which was assessed at 11.3 trillion in 2021 and is predicted to increase at a CAGR of 6.3% to reach 14.4 trillion in 2025.
Despite having a low outsourcing penetration rate of 7–12%, sales and marketing accounted for the greatest portion of life sciences operations spending 36% of the total.
There is still room for growth since outsourcing spending in this area is anticipated to increase at a CAGR of 11.3% between 2021 and 2025.
Through their Enterprise Commercial Solutions, they have already gained a foothold in this market and generated 61.04%, of their operating revenue for the FY22 from it.
Clientle
More than 70.00% of their total revenue from ongoing operations for each of the financial years 2022, 2021, and 2020 came from these 19 clients. They have built client connections with 19 of the 20 largest biopharmaceutical businesses in the world by revenue for the Financial Year 2021.
They had a total of 52 active clients as of June 30, 2022 (i.e., clients from whom they generated at least US$0.25 million in revenue over the 12 months prior to the pertinent date).
They had four clients who brought in more than US$25 million in income, three clients who brought in between US$10 million and US$25 million, and 21 clients from whom they made between US$1 million & US$10 million in sales.
Indegene IPO
Indegene Limited, headquartered in Ahmedabad has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 950 Crore and 36,291,497 equity shares on 14 December 2022.
The offer includes a fresh issue of INR 950 Crore and there is offer for sale (OFS) of 36,291,497 equity shares by the promoters mentioned in the DRHP. They are looking for any Pre-IPO placement of INR 190 Crore in this issue.
-
- Initial Public Offering
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 30-Jun-22 | 31-Mar-22 | 31-Mar-21 | 31-Mar-20 | ||
| Total Assets | 1,426.89 | 1353.47 | 596.04 | 600.25 | |
| Total Revenue | 539.71 | 1,690.50 | 996.92 | 646.38 | |
| Profit After Tax | 85.82 | 162.82 | 185.68 | 49.68 | |
Basic and Diluted Earnings Per Share
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2020 | (0.32) | (0.32) | 3 |
| Financial Year 2021 | 7.56 | 7.01 | 2 |
| Financial Year 2022 | 7.50 | 7.46 | 1 |
| Weighted Average | 6.22 | 6.01 | |
| 30 June 2022 | 3.88 | 3.86 |
Objects of the Issue
- Repayment/prepayment of debt owed by ILSL Holdings, Inc., one of its subsidiaries.
- Funding their Company’s and its Material Subsidiary, Indegene, Inc.’s capital expenditure requirements.
- ILSL Holdings, Inc., a subsidiary, paid consideration for the acquisition of additional shares in DT Associates Limited.
- General corporate objectives and organic growth.
Basis of the offer
Indegene limited feel that the following business strengths enable them to compete successfully in the industry, and that these factors will be used to calculate the Offer Price:
- Healthcare domain knowledge.
- Strong digital capabilities and a technology portfolio built in-house.
- Proven track record of developing long-term client connections.
- Model of global delivery.
- Experienced management and a committed personnel pool are backed by prominent investors.
- Acquisitions have a track record of adding value.
Indegene Peer Comparison
There are no publicly traded companies in India or throughout the world of comparable size, industry, or business strategy as their Company. As a result, they have not supplied an industry comparison for their Company.
Indegene IPO Details
| IPO Opening Date | April 2023 |
| IPO Closing Date | April 2023 |
| Issue Type | Book Building |
| Face Value | 02 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | – |
| Min Amount | – |
| Listing At | BSE, NSE |
| Issue Size | 950 Crore & 36,291,497 equity shares |
| Fresh Issue | 950 Crore |
| Offer for Sale | 36,291,497 equity shares |
Indegene IPO Date
Indegene Limited IPO opening date is April 2023, and the closing date is April 2023. The Indegene issue may list in April 2023.
| IPO Opening Date | April 2023 |
| IPO Closing Date | April 2023 |
| Basis of Allotment Date | April 2023 |
| Initiation of Refunds | April 2023 |
| Credit of Shares to Demat Account | April 2023 |
| IPO Listing Date | April 2023 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 75 |
Roughly equivalent
|
| Non Institutional Investor | 15 |
Roughly equivalent
|
| Retail | 10 | Minimum 1 lot based on availability |
Indegene IPO Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Indegene IPO.
Indegene IPO GMP
Indegene Limited IPO Grey Market Premium is 0. You can check out GMP of Other IPOs on below Links:
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 | |||
| April 2023 |
Check Out the GMP of all Other IPOs
Indegene Limited IPO Review
Indegene Limited IPO review will depend on the price band which will be announced after SEBI approval. Whenever it will be announced we will update you regarding review of Indegene IPO is good or bad.
Indegene Limited IPO Risk
- If they are unable to produce new client engagements, it may have a negative impact on their business, cash flows, and results of operations.
- If their client engagements are canceled or decreased in scope, the impact on their business, cash flows, and results of operations may be negative.
- They are subject to regulatory obligations in the delivery of services under their client contracts, and failure to comply with such regulations may have a negative impact on their reputation, business, financial condition, results of operations, and cash flows.
- If companies fail to supply solutions in accordance with contractual obligations, they may face considerable expenses or responsibility, and their reputation, financial situation, operating results, and cash flows may suffer as a result.
Other Threats
- The life sciences operations industry is highly competitive, and future prospects are difficult to forecast. Certain large clients in North America and Europe account for a sizable amount of their business.
- Any deterioration in their financial position or prospects, as well as any adverse developments in economic and political conditions in these regions, may have a negative influence on their Business.
- Their foreign operations subject them to complicated management, legal, tax, and economic risks, as well as currency rate changes, which could have a negative impact on their business, and operating results.
- Their failure to meet their obligations, including financial and other covenants under their debt financing arrangements, may have a negative impact on their business, financial situation, & cash flow.
Indegene Limited IPO Brokerage views
Once the dates will be announced we will update the views of different brokerage firms regarding this IPO. Here is the views of different stock brokers regarding this Indegene IPO:
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Indegene Limited IPO Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| April 2023 | 1 | |||||
| April 2023 | 2 | |||||
| April 2023 | 3 |
Indegene Limited Management
Many of their Key Managerial Personnel have over 20 years of experience in the healthcare industry & have business degrees or certifications from various medical institutes.
They have substantial experience in marketing and technology jobs within the healthcare sector. They have improved their topic knowledge thanks to their academic backgrounds and professional experiences.
Since the company’s founding, they have effectively led it by creating each of its business areas, increasing its reach internationally, and obtaining money from shareholders.
Their key managerial staff is dispersed around the world, with offices in India, the US, and the Uk. They have backgrounds in marketing, life sciences, and digital transformation. Their senior management team includes some people who have previously worked for clients of theirs.
Awards
Furthermore, they engage in information sharing and have been acknowledged as a thought leader in the healthcare business due to their extensive subject experience. They organize the annual Indegene Digital Summit, which features many keynote speakers and senior life sciences executives.
The Organization of Pharmaceutical Producers of India awarded them the “Special Recognition Award for Innovation in Health” in 2016 for their commitment to developing solutions that help global healthcare organizations to manage challenging challenges and enhance patient outcomes.
They were also named a “Leader” in Everest Group’s Life Sciences Commercial Services Specialists PEAK Matrix Assessment 2022 at the MM+M Awards in 2022 for their usage of integrated data platforms to deliver comprehensive patient insights.
Indegene Limited‘ Principal Shareholders
- Nadathur Group
- Vida Trustees Private Limited
- CA Dawn Investments
Principal Shareholders’s Holding
| Pre Issue Share Holding | 72.50% |
| Post Issue Share Holding |
Indegene Limited Prospectus
Contact Details
Indegene Limited
Aspen Block G4, 3
rd Floor, Manyata Embassy
Business Park, Outer Ring Road, Nagawara,
Bengaluru 560 045, Karnataka, India
Email: [email protected]
Telephone: +91 80 4674 4567/ +91 80 4644 7777
Website: www.indegene.com
Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
L.B.S. Marg Vikhroli West Mumbai – 400 083
Maharashtra, India
Tel: +91 22 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory and Securities (India) Private Limited
We hope we are able to answer all your questions about Indegene IPO. If you don’t have a Demat account, open it now with Zerodha best trading app of India.
Disclaimer
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
Profit must do not engage in grey market trading or facilitate the purchase or sale of IPO forms. We don’t endorse such activities at all. We are sticky against such activities & never advise anyone to trade in grey market at all.
FAQ
Indegene Limited IPO Opening Date?
Indegene Limited IPO will open in April 2023.
Indegene Limited IPO Listing Date?
Indegene Limited IPO will list in April 2023.
Indegene IPO GMP Today?
Indegene IPO Grey Market Premium is INR 0 .
Indegene Limited IPO Allotment Date?
Indegene Limited IPO basis of allotment will be in April 2023.
Lot size for Indegene Limited IPO?
Lot size for Indegene Limited IPO is 0.
